Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.16.2 (
PCP
)
3,761
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The
myopathy
induced in the rat by the central nervous system stimulant, phencyclidine (
PCP
), and restraint is characterized by extensive myofibrillar sarcomere disruption in hind limb muscles and massive increases in plasma creatine kinase (CPK) activity. The effects of dantrolene sodium on this
myopathy
were studied to determine if modulation of calcium release from the sarcoplasmic reticulum could alter the development of the
myopathy
. Dantrolene prevented both the sarcomere disruption and the increase in plasma CPK activity produced in the
PCP
-restraint model. The inhibitory effect was not due to a decrease in the locomotor activity produced by
PCP
. The findings are consistent with a role for excess sarcoplasmic calcium, originating from the sarcoplasmic reticulum, in the development of this
myopathy
.
...
PMID:Retention of sarcoplasmic calcium inhibits development of the phencyclidine-restraint experimental myopathy. 682 47
Background The 2013 American College of Cardiology/American Heart Association Cholesterol Treatment Guideline increased the number of primary prevention patients eligible for statin therapy, yet uptake of these guidelines has been modest. Little is known of how primary care provider (
PCP
) beliefs influence statin prescription. Methods and Results We surveyed 164
PCP
s from a community-based North Carolina network in 2017 about statin therapy. We evaluated statin initiation among the
PCP
s' statin-eligible patients between 2014 and 2015 without a previous prescription. Seventy-two
PCP
s (43.9%) completed the survey. The median estimate of the relative risk reduction for high-intensity statins was 45% (interquartile range, 25%-50%). A minority of providers (27.8%) believed statins caused diabetes mellitus, and only 16.7% reported always/very often discussing this with patients. Most PCPs (97.2%) believed that statins cause
myopathy
, and 72.3% reported always/very often discussing this with patients. Most (77.7%) reported always/very often using the 10-year atherosclerotic cardiovascular disease risk calculator, although many reported that in most cases other risk factors or patient preferences influenced prescribing (59.8% and 43.1%, respectively). Of 6172 statin-eligible patients, 22.3% received a prescription for a moderate- or high-intensity statin at follow-up. Providers reporting greater reliance on risk factors beyond atherosclerotic cardiovascular disease risk were less likely to prescribe statins. Conclusions Although beliefs and approaches to statin discussions vary among community
PCP
s, new prescription rates are low and minimally associated with those beliefs. These results highlight the complexity of increasing statin prescriptions for primary prevention and suggest that strategies to facilitate standardized discussions and to address external influences on patient beliefs warrant future study.
...
PMID:Association of Primary Care Providers' Beliefs of Statins for Primary Prevention and Statin Prescription. 3068 91